Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
about
Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based ImmunogensHuman Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic StructureCo-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cellsAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesBroader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles.Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesDNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic.Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Hepatitis C virus, human immunodeficiency virus and Pseudomonas phage PS5 triad share epitopes of immunogenic determinantsIdentification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.Back to the future: covalent epitope-based HIV vaccine development.Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designImproving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formationFunctional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFLProduction and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.Assessment of mucosal immunity to HIV-1.Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.
P2860
Q27658173-9E78CBD9-AC6A-4629-AA1B-727F3F76801CQ27676155-FE0364BF-66F5-4A00-8A5A-8563B8B77EC6Q28732043-6ECB4A3E-7689-4013-8C94-A58A91274D9AQ28752503-6B03AEBB-BB88-422C-8AA3-53383075FD1DQ30418340-F67A8A12-E06E-4DF1-BB2D-6D344B3E2D42Q30994182-BA805BD5-D88E-488D-90F6-6B8EB1334370Q31028199-520BB420-6C68-49CC-9262-E24ABC283D74Q33759392-E1791634-4A9A-41E5-A4FD-39CCD891F062Q33820645-F087E02B-427D-47F3-9680-9220E652CDCBQ34100194-34A46277-E0CE-441D-AD10-14868521CF9DQ34128200-B1148752-F5F2-4CA1-9FA4-A8E8A1FAEDBBQ34204047-1CD25D00-1607-4DD8-8707-D5A95D710B6AQ34426709-7F257D13-C13D-42AC-957C-344C1729F39AQ34488183-F251B9CA-4878-4116-AFBC-DD96FE316A51Q34597300-CDB77F12-77BC-40F4-B55E-F69A642FE75CQ35196671-4FFF5DB1-D157-45BE-938C-EFA6045EA89DQ35893538-886FCC37-2EDC-40D0-968F-307BD93EED12Q35913910-C339A074-9356-4DC9-B9B7-C3DDCAC42633Q36384117-1325520B-DAC9-4C99-9D65-1505845499B3Q36920319-9FD28EE9-6F1F-4BE7-9A63-4D56E6BC69B9Q37724856-5529621C-0489-4DD2-BCD3-1D57858DF224Q38968180-74BEBDBB-CA91-4C41-949B-F3A0B7A1ABB5Q42204816-78C9388A-CF9F-429B-B87B-78454B88B17DQ47555452-879F6F2A-FEB1-411F-997D-80A25929FFE6
P2860
Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cross-clade neutralizing antib ...... nse on a neutralizing epitope.
@en
Cross-clade neutralizing antib ...... nse on a neutralizing epitope.
@nl
type
label
Cross-clade neutralizing antib ...... nse on a neutralizing epitope.
@en
Cross-clade neutralizing antib ...... nse on a neutralizing epitope.
@nl
prefLabel
Cross-clade neutralizing antib ...... nse on a neutralizing epitope.
@en
Cross-clade neutralizing antib ...... nse on a neutralizing epitope.
@nl
P2093
P2860
P1433
P1476
Cross-clade neutralizing antib ...... onse on a neutralizing epitope
@en
P2093
Abraham Pinter
Sandra Cohen
Shixia Wang
Susan Zolla-Pazner
Terri Wrin
P2860
P356
10.1016/J.VIROL.2009.05.039
P407
P577
2009-07-26T00:00:00Z